Alai, Ksenistat, Orlip, Ortosen.
A peripheral agent for the treatment of obesity, a specific inhibitor of digestive lipases with a long-lasting effect.
Indications for use
Long-term therapy in combination with a moderately hypocaloric diet in obese patients with a body mass index (BMI) ≥ 30 kg / m² or in patients with overweight and BMI ≥ 28 kg / m², including those with obesity-associated risk factors.
Method of administration and dosage
The recommended dose is 120 mg with each main meal. If a meal is missed, then the drug can also be skipped. The patient should receive a balanced, moderately hypocaloric diet containing no more than 30 % fat . The daily ration must be divided into 3 main doses. The use of the drug in a dose exceeding the recommended dose does not enhance its therapeutic effect. The effect of the drug in persons with liver or kidney disease, as well as in children, has not been studied.
Possible oily discharge from the rectum, gas with some of the contents of the colon, urge to defecate, steatorrhea, increased frequency of bowel movements and fecal incontinence.
Chronic malabsorption syndrome, cholestasis, hypersensitivity to orlistat or other components of the drug, pregnancy and lactation, age up to 18 years.
Overdose cases are not described.